.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,017,900

« Back to Dashboard

Details for Patent: 6,017,900

Title: Topical composition containing hyaluronic acid and nsaids
Abstract:A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of hyaluronic acid or salts thereof or homologues, analogues, derivatives, complexes, esters, fragments, or sub-units of hyaluronic acid to transport the drug to the site of the pathology or trauma of the disease or condition.
Inventor(s): Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel Simon (Toronto, CA)
Assignee: Hyal Pharmaceutical Corporation (Missisauga, CA)
Filing Date:Jun 06, 1995
Application Number:08/466,775
Claims:1. A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to a site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of at least about 5 mg/cm.sup.2 of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and salts thereof to transport the drug percutaneously to the site of the pathology or trauma of the disease or condition wherein the form of hyaluronic acid is between about 1% and about 3% by weight of the composition having a molecular weight less than 750,000 daltons and greater than 150.000 daltons, and wherein the drug is between about 1% and about 5% by weight of the composition.

2. The composition of claim 1 suitable for topical application further comprising methoxypolyethylene glycol (20% by weight), benzyl alcohol (1% by weight), and sterile water in a container.

3. The composition of claim 2 wherein the form of hyaluronic acid is sodium hyaluronate and the drug is diclofenac sodium.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc